DR. BARBARA A GILCHREST, MD
Dermatology at Albany St, Boston, MA

6696303, Feb 24, 2004

May 29, 2001

09/866898

Barbara A. Gilchrest - Boston MA
Mina Yaar - Sharon MA

Trustees of Boston University - Boston MA

G01N 33563

436512, 436501, 435 71, 435 721, 435 78, 530300, 514 2

Methods for evaluating the risk of an individual to develop Alzheimers disease using cultured neural crest-derived melanocytes are described. Also described are methods of therapy for Alzheimers disease using peptides that bind to the neurotrophin receptor (p75 ) and competitively inhibit the binding of -amyloid to the p75.

2012023, Sep 20, 2012

Jul 16, 2010

13/383372

Barbara Ann Gilchrest - Boston MA, US
Gary Chuang - Boston MA, US

TRUSTEES OF BOSTON UNIVERSITY - Boston MA

A61B 10/02, A61B 10/06

600567, 600562, 600564

The present invention relates to a biopsy device, methods, kits and systems for marking the location of a biopsy site in order to later identify the location of a biopsy or surgery in a subject, where the marker is a dye or tattoo which is not visible to the naked eye under normal (white) light, but is visible under UV light. Some embodiments relate to marking a biopsy site for later visualization of the marker.

5962417, Oct 5, 1999

Sep 24, 1998

9/160126

Barbara A. Gilchrest - Boston MA
Hee-Young Park - Chelsea MA

Trustees of Boston University - Boston MA

A61K 3800, C12N 916

514 12

Methods are described whereby vertebrate skin, hair, wool or fur may be lightened, or darkened, in color by administration of a substance, e. g. , peptide, antibody, antibody fragment or DNA sequence encoding a peptide, that modulates the protein kinase C-beta-mediated activation of tyrosinase, the rate-limiting enzyme in melanogenesis.

2006018, Aug 17, 2006

Apr 24, 2006

11/409706

Barbara Gilchrest - Boston MA, US
Mark Eller - Boston MA, US
Mina Yaar - Sharon MA, US

A61K 48/00

514044000

Described are methods for treating hyperproliferative disorders, including cancers, by administering to the affected mammal (e.g., human) an effective amount of a composition comprising pTT or a composition comprising one or more oligonucleotides which share at least 50% nucleotide sequence identity with the human telomere overhang repeat. Methods of treatment or prevention of hyperproliferative diseases or pre-cancerous conditions affecting epithelial cells, such as psoriasis, atopic dermatitis, or hyperproliferative or UV-responsive dermatoses, hyperproliferative diseases of other epithelia and methods for reducing photoaging, or oxidative stress or for prophylaxis against or reduction in the likelihood of the development of skin cancer, are also disclosed.

6867179, Mar 15, 2005

Aug 4, 2000

09/632748

Barbara A. Gilchrest - Boston MA, US
Mina Yaar - Sharon MA, US
Mark Eller - Boston MA, US

Trustees of Boston University - Boston MA

A61K038/08, A61K038/17, A61K038/18

514 2, 514 12, 514 17, 514 15

Methods to control, or manipulate, melanocyte and keratinocyte cell death are disclosed. In particular, a method of preventing epidermal melanocyte cell loss due to injury in a vertebrate is disclosed. Also disclosed is a method of inducing hair growth in a vertebrate, a method of inducing hair color in a vertebrate, a method of inducing skin color in a vertebrate, a method of treating baldness in an individual, and a method of treating alopecia areata in an individual.

6147056, Nov 14, 2000

Mar 26, 1998

9/048927

Barbara A. Gilchrest - Boston MA
Mina Yaar - Sharon MA
Mark Eller - Boston MA

Trustees of Boston University - Boston MA

A61K 4800, A61K 9127, A61K 3170

514 44

Methods of treatment or prevention of hyperproliferative diseases or pre-cancerous conditions affecting epithelial cells, such as psoriasis, vitiligo, atopic dermatitis, or hyperproliferative or UV-responsive dermatoses, hyperproliferative or allergically mediated diseases of other epithelia and methods for reducing photoaging or for prophylaxis against or reduction in the likelihood of the development of skin cancer, are disclosed.

7033829, Apr 25, 2006

Apr 12, 2002

10/122633

Barbara A. Gilchrest - Boston MA, US
Mark S. Eller - Boston MA, US
Mina Yaar - Sharon MA, US

Trustees of Boston University - Boston MA

C12Q 3/00

435375, 435 6, 435325, 435377, 514 44, 536 231, 536 245

Described are methods for treating hyperproliferative disorders, including cancers, by administering to the affected mammal (e. g. , human) an effective amount of a composition comprising pTT or a composition comprising one or more oligonucleotides which share at least 50% nucleotide sequence identity with the human telomere overhang repeat. Methods of treatment or prevention of hyperproliferative diseases or pre-cancerous conditions affecting epithelial cells, such as psoriasis, atopic dermatitis, or hyperproliferative or UV-responsive dermatoses, hyperproliferative diseases of other epithelia and methods for reducing photoaging, or oxidative stress or for prophylaxis against or reduction in the likelihood of the development of skin cancer, are also disclosed.

2008022, Sep 11, 2008

May 19, 2005

11/569243

Barbara A. Gilchrest - Boston MA, US
Mark S. Eller - Boston MA, US

A61K 31/70, C12Q 1/68, G01N 33/574, A61P 43/00, C12Q 1/02, G01N 33/566

514 44, 435 6, 435 723, 435 29, 436501

The use of modulators of WRN is described. Activators of WRN may be used to induce growth arrest, apoptosis or proliferative senescence, whereas inhibitors of WRN may be used to reduce growth arrest, apoptosis or proliferative senescence. Methods of identifying modulators of WRN are also described.

2006026, Nov 30, 2006

Jan 14, 2004

10/553001

Barbara Gilchrest - Boston MA, US
Mark Eller - Boston MA, US

TRUSTEES OF BOSTON UNIVERSITY - Boston MA

A61K 48/00, C12Q 1/68, G01N 33/574, A61K 38/54

435006000, 435007230, 514044000, 514012000

The use of modulators of Mre 11, tankyrase, the DNA damage pathway and MRN complex formation of the protection of mammals from failure of growth arrest, apoptosis or proliferative senescence.